Champions Oncology, Inc.
CSBR
Rank in Stocks
#21456
Champions Oncology, Inc. is dedicated to developing and commercializing... Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Share Price
$4.84
Last synced: 2026-11-09
Market Cap
$67.37M
Change (1 day)
1.04%
Change (1 year)
-30.86%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Champions Oncology, Inc. (CSBR)
Category
Healthcare
EPS for Champions Oncology, Inc. (CSBR)
EPS as of July 2026 TTM: $-0.08
According to Champions Oncology, Inc.'s latest financial reports, its current EPS (TTM) is $-0.08. At the end of 2025 the company had an EPS of $0.34, an increase over its 2024 EPS of $-0.54.
EPS history for Champions Oncology, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.08 | -123.24% |
| 2025 | $0.34 | -162.96% |
| 2024 | $-0.54 | 38.46% |
| 2023 | $-0.39 | -1,039.76% |
| 2022 | $0.04 | 50.36% |
| 2021 | $0.03 | -115.33% |
| 2020 | $-0.18 | -1,692.92% |
| 2019 | $0.01 | -108.69% |
| 2018 | $-0.13 | -79.69% |
| 2017 | $-0.64 | -46.67% |
| 2016 | $-1.20 | -20.53% |
| 2015 | $-1.51 | 13.53% |
| 2014 | $-1.33 | -38.71% |
| 2013 | $-2.17 | -2.25% |
| 2012 | $-2.22 | 64.44% |
| 2011 | $-1.35 | 29.81% |
| 2010 | $-1.04 | 28.40% |
| 2009 | $-0.81 | 575.00% |
| 2008 | $-0.12 | 20.36% |
| 2007 | $-0.10 | -16.92% |
| 2006 | $-0.12 | -45.45% |
| 2005 | $-0.22 | 46.67% |
| 2004 | $-0.15 | -37.50% |
| 2003 | $-0.24 | 0.00% |
| 2002 | $-0.24 | -77.78% |
| 2001 | $-1.08 | -19,047.37% |
| 2000 | $0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -19,922.78% |
US
|
|
| $-7.07 | 8,849.37% |
US
|
|
| $-5.29 | 6,596.20% |
AU
|
|
| $12.88 | -16,403.92% |
BE
|
|
| $21.56 | -27,391.14% |
NL
|
Questions about Champions Oncology, Inc.'s earnings per share (EPS)
What is Champions Oncology, Inc.'s earnings per share (EPS)?
Champions Oncology, Inc.'s earnings per share (EPS) over the last twelve months is $-0.08, as of Jul 2026.
What was Champions Oncology, Inc.'s earnings per share (EPS) in 2025?
In 2025, Champions Oncology, Inc.'s earnings per share (EPS) was $0.34, compared with $-0.54 in 2024.
How has Champions Oncology, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Champions Oncology, Inc.'s earnings per share (EPS) was highest in 2025 ($0.34) and lowest in 2024 ($-0.54).
How does Champions Oncology, Inc.'s earnings per share (EPS) compare with similar companies?
Champions Oncology, Inc.'s earnings per share (EPS) ($-0.08) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.